Compare Cronos Group Inc (CRON) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs IDEXX Laboratories, Inc. — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 34.3× Cronos Group Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| CRON | IDXX | |
|---|---|---|
Market Cap | $1.18B | $40.43B |
Volume | 968,037 | 692,164 |
Sector | Health | Health |
52-Week High | $3.55 | $766.68 |
52-Week Low | $2.30 | $504.70 |
Typical Hold Time | 22 Days | 46 Days |
Enterprise Value | $387.62M | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating earnings estimates with 58% YoY revenue growth, and maintains a robust balance sheet with $827 million in cash and no debt. Recent investor day highlighted expansion in Canada and international markets.
Outlook is mixed; profitability improved with net income margin turning positive in 2026 forecasts, but high EV/EBITDA of 43 suggests premium valuation. Risks include execution of growth plans and cannabis sector volatility. Analyst consensus is cautious with 60% hold ratings.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
